Ahmad Miremadi
Overview
Explore the profile of Ahmad Miremadi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
1017
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Pilonis N, Killcoyne S, Tan W, ODonovan M, Malhotra S, Tripathi M, et al.
Lancet Oncol
. 2022 Jan;
23(2):270-278.
PMID: 35030332
Background: Endoscopic surveillance is recommended for patients with Barrett's oesophagus because, although the progression risk is low, endoscopic intervention is highly effective for high-grade dysplasia and cancer. However, repeated endoscopy...
12.
Killcoyne S, Gregson E, Wedge D, Woodcock D, Eldridge M, De La Rue R, et al.
Nat Med
. 2020 Sep;
26(11):1726-1732.
PMID: 32895572
Recent studies show that aneuploidy and driver gene mutations precede cancer diagnosis by many years. We assess whether these genomic signals can be used for early detection and pre-emptive cancer...
13.
Januszewicz W, Subhash V, Waldock W, Fernando D, Bartalucci G, Chettouh H, et al.
EBioMedicine
. 2020 Jul;
58:102877.
PMID: 32707444
Background: Radiofrequency ablation (RFA) is an effective treatment for dysplastic Barrett's esophagus (BE), but recurrence can occur after initial response. Currently there is uncertainty about how to best define histological...
14.
Noorani A, Li X, Goddard M, Crawte J, Alexandrov L, Secrier M, et al.
Nat Genet
. 2020 Jan;
52(1):74-83.
PMID: 31907488
The poor outcomes in esophageal adenocarcinoma (EAC) prompted us to interrogate the pattern and timing of metastatic spread. Whole-genome sequencing and phylogenetic analysis of 388 samples across 18 individuals with...
15.
Xu Y, Miremadi A, Link A, Malfertheiner P, Fitzgerald R, Bornschein J
J Clin Pathol
. 2019 Jun;
72(12):825-829.
PMID: 31235543
Aims: Aim was to assess the feasibility of serum markers to identify individuals at risk for gastro-oesophageal adenocarcinoma to reduce the number of individuals requiring invasive assessment by endoscopy. Methods:...
16.
Bornschein J, Wernisch L, Secrier M, Miremadi A, Perner J, MacRae S, et al.
Int J Cancer
. 2019 May;
145(12):3389-3401.
PMID: 31050820
Cancers occurring at the gastroesophageal junction (GEJ) are classified as predominantly esophageal or gastric, which is often difficult to decipher. We hypothesized that the transcriptomic profile might reveal molecular subgroups...
17.
Turkington R, Knight L, Blayney J, Secrier M, Douglas R, Parkes E, et al.
Gut
. 2019 Mar;
68(11):1918-1927.
PMID: 30852560
Objective: Current strategies to guide selection of neoadjuvant therapy in oesophageal adenocarcinoma (OAC) are inadequate. We assessed the ability of a DNA damage immune response (DDIR) assay to predict response...
18.
Li X, Francies H, Secrier M, Perner J, Miremadi A, Galeano-Dalmau N, et al.
Nat Commun
. 2018 Aug;
9(1):2983.
PMID: 30061675
Esophageal adenocarcinoma (EAC) incidence is increasing while 5-year survival rates remain less than 15%. A lack of experimental models has hampered progress. We have generated clinically annotated EAC organoid cultures...
19.
Li X, Kleeman S, Coburn S, Fumagalli C, Perner J, Jammula S, et al.
Gastroenterology
. 2018 Jun;
155(3):771-783.e3.
PMID: 29906417
Background & Aims: MicroRNA (miRNA) is highly stable in biospecimens and provides tissue-specific profiles, making it a useful biomarker of carcinogenesis. We aimed to discover a set of miRNAs that...
20.
Secrier M, Li X, de Silva N, Eldridge M, Contino G, Bornschein J, et al.
Nat Genet
. 2017 Feb;
49(2):317.
PMID: 28138154
No abstract available.